A phase I clinical trial (NCT02683083) of 131I-SGMIB-2Rs15d in healthy volunteers and patients with HER2-positive BC shows a high tumor to background ratio, rapid blood clearance, and elimination of unbound nanobodies via the kidney after intravenous administration. This evidence concerns the gene ERBB2 and neoplasm.